Last reviewed · How we verify
Levulan — Competitive Intelligence Brief
marketed
Optical Imaging Agent
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Levulan (AMINOLEVULINIC ACID) — Sun Pharma. Levulan accumulates in abnormal skin cells, allowing for visualization and treatment.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Levulan TARGET | AMINOLEVULINIC ACID | Sun Pharma | marketed | Optical Imaging Agent | 1999-01-01 | |
| Cytalux | PAFOLACIANINE | On Target Labs | marketed | Optical Imaging Agent | Folate receptor alpha | 2021-01-01 |
| submucosal injection of indocyanine green | submucosal injection of indocyanine green | Fujian Medical University | phase 3 | Optical imaging agent / surgical tracer |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Optical Imaging Agent class)
- On Target Labs · 1 drug in this class
- Sun Pharma · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Levulan CI watch — RSS
- Levulan CI watch — Atom
- Levulan CI watch — JSON
- Levulan alone — RSS
- Whole Optical Imaging Agent class — RSS
Cite this brief
Drug Landscape (2026). Levulan — Competitive Intelligence Brief. https://druglandscape.com/ci/aminolevulinic-acid. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab